pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › MNKD

MNKD PDUFA Date: FUROSCIX ReadyFlow Autoinjector (SCP-111)

FDA decision (PDUFA) target 2026-07-26 · MannKind Corporation · Edema in adult patients with chronic heart failure (CHF) or chronic kidney disease (CKD)

MNKD run-up into the PDUFA (last ~120 days)

$5.57$2.28
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-07-26
Drug / candidateFUROSCIX ReadyFlow Autoinjector (SCP-111)
IndicationEdema in adult patients with chronic heart failure (CHF) or chronic kidney disease (CKD)
CompanyMannKind Corporation
Market-cap tierSmall
Cohort decision-day move (history)±3% median
ClinicalTrials.gov—

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the MNKD PDUFA date?
The FDA PDUFA target date for MNKD (MannKind Corporation) is 2026-07-26 for FUROSCIX ReadyFlow Autoinjector (SCP-111). Dates are company/FDA-sourced and can slip — verify against primary filings.
What is MNKD's drug FUROSCIX ReadyFlow Autoinjector (SCP-111)?
FUROSCIX ReadyFlow Autoinjector (SCP-111) is MannKind Corporation's candidate under FDA review for Edema in adult patients with chronic heart failure (CHF) or chronic kidney disease (CKD).
What typically happens to a small-cap stock into a PDUFA date?
Historically, small-cap names had a median decision-day move around ±3% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.